The Trump administration is issuing one-time $90 payments to more than 20 million Medicare beneficiaries to help cover Part B premiums, though the payments may do little to offset rising healthcare costs.
CMS cited rising drug costs and the Covid-19 pandemic as the reason for the premium increases, which will rise to $170 in 2022 for people who make $91,000 or less.
In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.
The U.S. district attorney for Massachusetts filed suit against the drugmaker this week, alleging that it paid tens of millions in kickbacks through a copay foundation for Eylea, a drug used to treat macular degeneration.
The aim, the government says, is to maintain quality while slowing spending in Medicare Part B by more closely tying payments to how well drugs work, using methods drugmakers, insurers and benefit managers are already trying in the private sector.
Tom Lee, founder and CEO of SA Ignite, discusses why the new Medicare Merit-based Incentive Payment System, or MIPS, could be an administrative headache for medical practices and a boon for his company.
The huge rate hike is predicted because of a confluence of two factors: Medicare Part B costs increased more than expected last year, and Social Security is not expected to have a cost of living increase next year.
Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.